Daré Bioscience, Inc.

$DARE CEO Sabrina Martucci Johnson attended the Forbes 30/50 Summit as a 2026 Forbes 50 Over 50 honoree. Inspiring panels, including remarks from Hillary Clinton, reinforced the urgent need to address maternal mortality and advance women's health. Thank you, Forbes! @Forbes

Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum bit.ly/3UoDMx0 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

We had the chance to meet Dr. Jill Biden at The Menopause Society Annual Meeting, where she delivered this year's keynote. As Chair of the Milken Institute Women's Health Network, Dr. Biden is a steady champion for investment in women's health research. $DARE #WomensHealth

At the WME Women's Health Summit last week, Secretary Xavier Becerra and Biocom chair and President Sabrina Johnson connected with Assembly member Rebecca Bauer-kahan on the research gaps and policy decisions shaping women's care. @wme @wmecommunity $DARE #WomensHealth

Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion bit.ly/4jLtSQd $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly bit.ly/3WvlTNw $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

The White House issued an Executive Order on Advancing Women's Health to Improve Outcomes in All Phases of Life, including a new Women's Health Division at the National Institutes of Health. Read more: bit.ly/4zHKuNx $DARE #WomensHealth

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer bit.ly/4hSi5hL $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

CEO Sabrina Martucci Johnson shares insights into $DARE's growing commercial portfolio, clinical pipeline and strategic priorities, including the Company's transition to a commercial-stage women's health company in their new CEO Corner Series. 🔗: bit.ly/47ez5Zx

Daré Bioscience Launches "CEO Corner" Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities bit.ly/4hHrZCN $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting bit.ly/4hIlPB6 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection bit.ly/4hQBob6 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil bit.ly/3TwiRHI $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand. View the video webcast here: bit.ly/4iW53k3 bit.ly/46nIXj4 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth bit.ly/4gtUxPD $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series Video webcast now available here: bit.ly/4xrzu6g bit.ly/4hXC0fJ $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society bit.ly/4x0N13O $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

🚌We've reached our final stop! The final Virtual Bus Tour event begins today at 3:30 PM ET. Listen in as CEO Sabrina Martucci Johnson shares our business overview and answers investor questions during a live Q&A. bit.ly/4cHs86a

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment bit.ly/4gr5m3t $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List bit.ly/4wEpuW7 $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare